Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interpretation of Chemistry, Hematology and Coagulation Laboratory Results in Early-Phase Clinical Pharmacology Trials; a Retrospective Analysis Based on the Placebo Arm of Randomized-Controlled Trials.

Clinical and translational science·2026
Same author

Method-Dependent Variability in Late Gadolinium Enhancement Quantification Before and After Left Atrial Ablation.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance·2026
Same author

Early immune responses to intradermal lipopolysaccharide in healthy volunteers: prednisolone's impact on TLR4-mediated inflammation.

Frontiers in immunology·2026
Same author

Living tissues and dead objects in the eye: The first description of ocular immune privilege by J.C. van Dooremaal in Albrecht Von Graefe's Archiv für Ophthalmologie in 1873.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Dominant Frequency Mapping as a Functional Tool for Substrate-Guided Ventricular Tachycardia Ablation.

Journal of cardiovascular electrophysiology·2026
Same author

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early-Phase Oncology Drug Development.

Clinical pharmacology and therapeutics·2026
Same journal

AI is Excellent at the Discovery and Identification of Unrecognized Scientific Knowledge but There Is No Evidence That AI Can Create New Scientific Knowledge.

Journal of clinical pharmacology·2026
Same journal

Ketamine Dosing Across Clinical Indications: A Narrative Review Organized by Proposed NMDA-Related Mechanisms.

Journal of clinical pharmacology·2026
Same journal

Flip-Flop Pharmacokinetics in Pregnancy and the Future of Obstetric Pharmacology.

Journal of clinical pharmacology·2026
Same journal

Correction to "A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants With End-Stage Kidney Disease on Hemodialysis".

Journal of clinical pharmacology·2026
Same journal

Street Pharmacology: The Mechanistic Basis of Clinical Pharmacology Underlying the Microdosing Method of Buprenorphine-Naloxone With a Focus on the Unhoused Population.

Journal of clinical pharmacology·2026
Same journal

Ontology-Enhanced Deep Learning for Mechanistic Prediction of Drug-Drug Interactions: A Clinically Interpretable Framework.

Journal of clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Clinically important interaction between tedisamil and verapamil.

Aernout D van Haarst1, Anneke C Dijkmans, Hans-Josef Weimann

  • 1Centre for Human Drug Research, Leiden, The Netherlands.

Journal of Clinical Pharmacology
|March 21, 2009
PubMed
Summary
This summary is machine-generated.

Concomitant use of tedisamil, an antiarrhythmic drug, with verapamil, a P-glycoprotein inhibitor, significantly increases tedisamil levels and prolongs QTc interval, indicating a clinically significant drug interaction.

Related Experiment Videos

Last Updated: Jun 24, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Area of Science:

  • Pharmacology
  • Clinical Pharmacology
  • Drug Interactions

Background:

  • Tedisamil is a class III antiarrhythmic drug that is a substrate for P-glycoprotein.
  • Coadministration with verapamil, a class IV antiarrhythmic and P-glycoprotein inhibitor, is a potential clinical scenario.
  • Understanding these interactions is crucial for patient safety.

Purpose of the Study:

  • To evaluate the pharmacokinetic and pharmacodynamic interactions between tedisamil and verapamil.
  • To assess the impact of coadministration on drug concentrations and cardiac electrophysiology.

Main Methods:

  • A double-blind, crossover study involving twelve healthy volunteers.
  • Participants received tedisamil, verapamil, a combination, or placebo for 3 days.
  • Measurements included blood pressure, electrocardiograms, cardiac output, and pharmacokinetics.

Main Results:

  • Combination therapy significantly increased tedisamil plasma concentrations (AUC: +77%, Cmax: +78%).
  • Verapamil and norverapamil plasma concentrations decreased with combination therapy (AUC: -21% and -17%, Cmax: -28% and -20%).
  • Combination treatment led to significant increases in QTc interval compared to placebo.

Conclusions:

  • Concomitant use of tedisamil with P-glycoprotein inhibitors like verapamil results in clinically significant drug interactions.
  • Increased tedisamil exposure and QTc prolongation are key concerns.
  • Caution is advised when prescribing these drugs together.